Choosing the right cryonics provider

I understand the attraction of a provider comparison table.

Price on one line. Membership fee on another. Add a few ticks for services, then choose the column with the most ticks.

This works reasonably well for a laptop. It is a dangerous way to choose a cryonics provider.

A provider is not one product. It is a chain of people, vehicles, medical procedures, documents, quality checks, legal entities, capital and long-term storage.

That chain may have to work on the worst day of your family's life. You will not be able to supervise it.

So yes, compare providers. Please do. We publish a detailed, current cryonics provider comparison precisely because the differences matter.

But compare the complete system, not the headline price.

We are not neutral. We believe Tomorrow.bio is the strongest available option today. Here is the evidence you should check before agreeing with us.

Start with the first hours

People naturally look first at the storage facility. It is tangible. You can photograph a dewar, walk through a building and imagine where you would be kept.

The first hours are less photogenic and often more important.

After legal death, biological change continues. Someone needs to notify the provider, a trained team needs to reach the patient, and cooling and stabilisation need to begin as quickly as circumstances allow.

A magnificent facility cannot recover time lost before the patient started moving towards it.

This is why the first comparison questions should be almost boringly practical. Where are the teams? Who employs them? Are they available around the clock? What equipment reaches you? What can they do at your location?

Do not accept an answer about a provider's best-covered city when you live somewhere else.

Tomorrow.bio maintains active response capacity across Europe and the United States. Our in-house standby, stabilisation and transport work is supported by dedicated ambulances and trained medical and surgical personnel.

When conditions allow, our standard approach is whole-body field cryoprotection. We aim to replace blood with cryoprotective solution in an equipped ambulance before long-distance transport, instead of waiting until the patient reaches Switzerland.

The distinction is important. Transport then follows the core preservation procedure. It does not postpone it.

You can read the process in first response and standby, field perfusion and cryoprotection, and our account of what happens when a member needs us.

There will always be difficult cases. Sudden deaths happen. Access can be delayed. Families and authorities can create complications.

A serious provider does not pretend geography has disappeared. It builds dense coverage where its members live, prepares for travel cases, and tells you honestly where the limits are.

This appeared clearly in our member research. Some people liked cryonics for years, but a distant organization never felt operationally real. Regional response capacity changed the question from "do I believe in cryonics?" to "can this work where I live?"

That is anonymous context from a limited set of interviews, not a claim about every member. Still, the concern is completely rational.

Ask for evidence from real cases

Every provider can describe a protocol.

A protocol tells you what the team intends to do. A case report tells you what happened when a call came late, circulation was difficult, paperwork took longer than expected, or the patient was far from the nearest team.

You need both.

Tomorrow.bio publishes numbered case reports with timelines, temperatures, procedural data, deviations and outcomes. We also discuss them publicly. That creates an uncomfortable but useful discipline: the real case can be compared with the intended protocol.

If an organization only shows polished procedures, ask what it learned from its last difficult case.

Then ask how preservation quality is measured. "The procedure was completed" is not a quality metric.

Tomorrow.bio performs CT scans on every human patient at cryogenic temperature before long-term storage. The scans provide qualitative and quantitative evidence about cryoprotectant distribution and possible ice formation.

Using the same cryogenic conditions makes density measurements more comparable between patients. Our quality programme also includes work towards consented electron microscopy, which can examine brain ultrastructure at a much smaller scale.

Neither method proves future revival. Nothing available today can prove that.

They do something more modest and extremely valuable: replace reassurance with inspectable evidence about what was preserved.

That evidence can expose a weak procedure. Good. That is how the next procedure becomes better.

We believe preservation quality should be measured patient by patient, case reports should be published, and technical claims should survive contact with actual data. Honestly, it is strange that this is not already the basic standard of the field.

Who is responsible after the procedure?

A provider comparison that ends when the patient enters storage is incomplete.

The storage period could last for decades or much longer. Founders will leave. Management will change. Technology, law, currencies and political conditions will change with them.

You should therefore ask a blunt question: who legally controls the patient and the money reserved for their care?

Tomorrow.bio separates these responsibilities across three organizations.

Tomorrow Biostasis GmbH operates the membership, response and cryopreservation service. The Patient Care Foundation is the legal guardian of the patient and their allocated capital. The European Biostasis Foundation operates the long-term storage and research facility in Switzerland.

These are sister organizations, not casual suppliers.

The separation matters because patient care should not depend on the continued commercial success of the operating company. Capital assigned to long-term care and patients already in storage do not simply sit on Tomorrow.bio's balance sheet.

The Swiss foundations publish financial accounts under the applicable oversight framework. Compare financial transparency, patient-care allocation, investment approach and legal separation of funds.

Do not settle for "we intend to be here for a long time." Everyone intends that.

Look for a structure built around founder succession and organizational failure. Our articles on the Tomorrow.bio ecosystem, organizations meant to last, and what happens if Tomorrow.bio goes bankrupt explain the design in more detail.

Facility design belongs in the same conversation. EBF operates a purpose-built underground facility in Switzerland, with liquid-nitrogen infrastructure, monitored storage systems and room to expand.

You can inspect the facility, its published activity, and the systems used for long-term patient care. A promise intended to last for generations should not be hidden behind a sales presentation.

Most organizations say they support research. The useful question is what changes because of it.

Is there an in-house team? Is there a published roadmap? Does engineering move from a prototype into ambulances, cooldown equipment, quality measurement and storage?

Tomorrow.bio has medical R&D and applied-engineering work inside the operating system. We publish a multi-year roadmap and update procedures as evidence improves.

This includes cryoprotective-agent development, field equipment, training models, computer-controlled cooldown, quality assessment and new storage technology.

Not every project will work. That is what research means.

The important point is that failures can be measured, learned from and converted into a better next version. Our articles on applied engineering and research and development show how this connects to patient care.

This is also why price should come late in the comparison, not first.

Ask what the quoted amount includes. Standby, field procedures, international transport, cooldown, long-term storage and patient-care capital may be bundled or separated.

A cheaper number attached to a smaller service is not evidence of better value. It is a different offer.

Why we believe Tomorrow.bio is the best choice

We built Tomorrow.bio because we thought cryonics could be done much better, particularly for people in Europe.

Today, our argument is no longer a plan on a slide.

We have active response infrastructure in Europe and the United States. We perform field cryoprotection as a standard approach when conditions allow. We publish case reports, perform CT scans of every human patient at cryogenic temperature, operate in-house research and engineering, and store patients at our sister organization's purpose-built Swiss facility.

Patient care and its capital are legally separated from the operating company. The relevant foundations operate under Swiss oversight and publish financial accounts.

That combination is why we believe Tomorrow.bio offers the strongest complete system available today.

No provider can promise revival. Tomorrow.bio cannot promise it either.

What we can do is build the best preservation and long-term-care chain we know how to build, measure the result, publish evidence, and keep improving it.

Read the full comparison matrix. Check the sources. Ask us difficult questions. Visit the Berlin operation and the Swiss facility if you can.

Then make the decision on the system that would actually have to carry you.

Further reading

• The full cryonics provider comparison
• What actually happens when you need us?
• How Tomorrow.bio measures preservation quality